
|Videos|May 25, 2016
- Gastrointestinal Cancers: mCRC (Issue 8)
Novel Targets in Gastric Cancer
Author(s)Manish Shah, MD
Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell discusses novel targets in gastric cancer outside of HER2.
Advertisement
Articles in this issue
about 10 years ago
Pessimism Surrounds VEGF Inhibitors in Advanced Gastric Cancerabout 10 years ago
Immunotherapies Provide Promising Results in Advanced Gastric Cancerabout 10 years ago
The Link Between Helicobacter Pylori and Gastric Cancerabout 10 years ago
Unmet Needs and Future Treatment Approaches in Gastric CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
3
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
4
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
5






























